Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysis

Authors

Institutions

Publication Details

Journal
Therapeutic Advances in Gastroenterology
Published
2025-10-01
DOI
https://doi.org/10.1177/17562848251383767
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysis

Jordi Guardiola, Perttu Arkkila, Jørgen Jahnsen, Stephen B. Hanauer et al.
Therapeutic Advances in Gastroenterology
Inflammatory Bowel Disease
article

Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysis

Jordi Guardiola, Perttu Arkkila, Jørgen Jahnsen, Stephen B. Hanauer, Walter Reinisch, Raja Atreya, Laurent Peyrin‐Biroulet, Silvio Danese, Philip J Smith, Alessandro Armuzzi, Seungmin Kim, Roberto Faggiani, Kiyeun Nam, Taek Sang Kwon, Jean–Frédéric Colombel, Marc Ferrante
article en

Abstract

No abstract available for this paper.
Therapeutic Advances in GastroenterologyVol. 18
Northwestern University (US), University of Helsinki (FI), Humanitas University (IT), University of Liverpool (GB), Vita-Salute San Raffaele University (IT), Inserm (FR), Friedrich-Alexander-Universität Erlangen-Nürnberg (DE), Akershus University Hospital (NO), Helsinki University Hospital (FI), McGill University Health Centre (CA), Bellvitge University Hospital (ES), Royal Liverpool University Hospital (GB), Institut d'Investigació Biomédica de Bellvitge (ES), Universitätsklinikum Erlangen (DE), IRCCS San Camillo Hospital (IT), Clinique Hartmann (FR), Comprehensive Cancer Center Erlangen (DE), Clinique Ambroise Paré (FR), Centre Hospitalier Universitaire de Saint-Étienne (FR), Celltrion (South Korea) (KR), IRCCS Humanitas Research Hospital (IT), Nutrition-Génétique et Exposition aux Risques Environnementaux (FR), Universitat de Barcelona (ES), Medical University of Vienna (AT), Icahn School of Medicine at Mount Sinai (US), KU Leuven (BE)
Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, Biogen, Celgene, Celltrion, United European Gastroenterology, Samsung, Cilag
Openalex Percentile: Top 70%
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.